Understanding how oxygen levels regulate immune responses could reshape how scientists approach inflammatory diseases and hypoxia-related conditions in humans — and this discovery complicates a long-held assumption about a key enzyme's role. The factor inhibiting HIF-1 (FIH), traditionally understood as an oxygen-sensing hydroxylase that modulates hypoxia pathways, turns out to have a parallel, enzymatically independent function in teleost fish that challenges textbook biochemistry.
In aquatic vertebrates (teleosts), FIH activates the pro-inflammatory NF-κB signaling pathway through an unconventional mechanism: physical competition with the p65 subunit of NF-κB for binding to its inhibitory partner IκBα, rather than through hydroxylation catalysis. When FIH competitively displaces p65 from IκBα, p65 is freed to enter the nucleus and drive immune gene expression. This was validated across cellular models and zebrafish fih-knockout lines (drfih−/−), confirming the pathway is functional in vivo and specific to the teleost lineage rather than a conserved vertebrate mechanism.
This finding carries nuanced implications for translational biology. FIH has been studied in mammalian systems primarily as a regulator of HIF-1α and ankyrin repeat proteins, with its hydroxylase activity considered its defining function. The revelation that FIH can operate as a structural competitor — independent of catalysis — introduces a protein-interaction paradigm that researchers may have systematically overlooked in mammals. It raises the question of whether analogous non-enzymatic moonlighting functions exist in human FIH under specific cellular conditions, such as severe hypoxia when hydroxylase activity is suppressed.
For longevity and immunology researchers, the broader significance lies in the oxygen–immunity interface: tissues experiencing low oxygen (tumors, aging vasculature, sleep apnea) may regulate NF-κB activity through mechanisms beyond canonical IKK-mediated IκBα phosphorylation. This study is a single-species mechanistic finding and should not be extrapolated to human therapeutics yet, but it meaningfully expands the conceptual framework for how oxygen-sensing proteins bridge metabolic status and inflammatory signaling.